This study is testing a new treatment for head and neck cancer that's come back or spread. It uses a TMV vaccine made from a patient's own tumor cells. The vaccine might help your body fight the cancer by making your immune system stronger. The study also uses a drug called pembrolizumab, which is an immunotherapy drug that helps the immune system attack cancer cells.
In this study, patients are split into two groups: one group gets only the TMV vaccine, and the other gets both the TMV vaccine and pembrolizumab. The study checks if this approach is safe and effective. Patients will have regular checkups, including scans and blood tests.
- Study involves regular visits every few weeks for up to a year.
- Participants must be 18 or older and have specific types of head and neck cancer.
- The study provides close monitoring of health and may involve some risks and side effects.
After the treatment, patients are monitored for up to 12 months to see how well the treatment works. Participants should be willing to commit to the study schedule and procedures.